Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05032404 Enrolling by invitation - Clinical trials for Breast Cancer Female

Blue Note Therapeutics Product BNT 103 Usability and User Engagement

Start date: September 2021
Phase: N/A
Study type: Interventional

This test aims to explore product development-focused usability and user engagement.

NCT ID: NCT04929197 Enrolling by invitation - Breast Cancer Clinical Trials

Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing

PERSBRA
Start date: April 21, 2016
Phase: N/A
Study type: Interventional

Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence. However, significant portions of the heart and the lungs are exposed to low dose radiation during radiotherapy, which result in stochastic side effects among breast cancer survivors. Inspired by 3D printing technology, we approached this issue with an in-house made PERSonalized BReAst holder system (PERSBRA). PERSBRA is composed of a 3D-printed plastic holder covering the whole breast and an air-filled interface. Its main function is to reproducibly adjust the breast position to decrease heart and lung radiation exposure in tangential fields. Here we propose to measure the performance of PERSBR in terms of radiation dosimetry in 50 patients receiving scheduled whole breast irradiation. For customized PERSBRA, body shape of the patient with or without a bustier corset will be captured with a handheld 3D scanner and input into a 3D printer for PERSBRA design and manufacturing. A participant will receive two more CT scans in addition to the simulation scan with PERSBRA in place before the first and the sixth fractions of irradiation. These images will be analyzed for dosimetric parameters in the presence/absence of PERSBRA as well as position reproducibility. The data will provide proof-of-principle evidence for the clinical utility of PERSBRA and will facilitate its further refinement.

NCT ID: NCT04928014 Enrolling by invitation - Healthy Clinical Trials

Clinical Utility for Melody®, a Tear-based Screening Assay for Breast Cancer

VIOLA
Start date: June 1, 2021
Phase:
Study type: Observational

The VIOLA Study is a Clinical Utility Study to explore and better understand the value, usage, and benefits of Melody®, a tear-based screening test for breast cancer. Melody® was developed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.

NCT ID: NCT04914494 Enrolling by invitation - Breast Cancer Clinical Trials

Cancer Predictive Score on Breast MRI

Start date: January 1, 2021
Phase:
Study type: Observational

Sometimes, breast ultrasound and mammographic can't be diagnose suspsious lesions ( no substratum). So a MRI-guided breast biopsy is perfomed and disclosed ultimately benign lesions. The aim of this retrospective study is to establish a predictive MRI score of occult breast lesions by mammography and ultrasound.

NCT ID: NCT04862078 Enrolling by invitation - Breast Cancer Clinical Trials

Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer

SMART-FU
Start date: July 6, 2021
Phase: N/A
Study type: Interventional

In this study, clinical impacts of shared decision making between physicians and patients in strategy of surveillance for asymptomatic patients who ended the primary treatments on quality of life would be investigated

NCT ID: NCT04839835 Enrolling by invitation - Breast Cancer Clinical Trials

Anxiety on the First Day of Chemotherapy

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

investigating chemotherapy anxieties

NCT ID: NCT04838756 Enrolling by invitation - Breast Cancer Clinical Trials

Mammography Screening With Artificial Intelligence (MASAI)

MASAI
Start date: April 12, 2021
Phase: N/A
Study type: Interventional

The purpose of this randomized controlled trial is to assess whether AI can improve the efficacy of mammography screening, by adapting single and double reading based on AI derived cancer-risk scores and to use AI as a decision support in the screen reading, compared with conventional mammography screening (double reading without AI).

NCT ID: NCT04767464 Enrolling by invitation - Breast Cancer Clinical Trials

Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups

CC-V
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The Compass Course (CC) is a group intervention designed for individuals with Breast Cancer. Over the course of 8 face-to-face group sessions, the CC is designed to help participants reclaim a sense of self-grounded purpose in daily life, defined as intentional use of time and energy in ways that align with one's values, strengths, and sources of personal meaning (e.g., inner compass) in the moments that compose a day. Because of COVID-19, in-person groups are discouraged and so we need to identify new ways to provide group-based interventions that are feasible and efficacious.

NCT ID: NCT04746638 Enrolling by invitation - Prostate Cancer Clinical Trials

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

The study should evaluate the biological distribution of 99mTc-RM26 in patients with prostate cancer and breast cancer. The primary objective are: 1. To assess the distribution of 99mTc- RM26 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of 99mTc- RM26. 3. To study the safety and tolerability of the drug 99mTc- RM26 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained 99mTc- RM26 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.

NCT ID: NCT04601272 Enrolling by invitation - Clinical trials for Breast Cancer Screening

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

Start date: September 29, 2020
Phase:
Study type: Observational

The purpose of this retrospective observational study is to evaluate the performance of the Shared Decision Making Process scale in a sample of patients who have received a decision aid about the decision to screen or not screen for breast cancer, colon cancer, prostate cancer, or lung cancer.